PT-141 (Bremelanotide) dosing & administration
The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much PT-141 (Bremelanotide) do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
1 mg
Frequency
As needed, ~45 min before sexual activity; no more than once per 24 h
Duration
Trial period (assess response/tolerability)
Not a labelled dose: VYLEESI comes only as a 1.75 mg single-dose autoinjector [7]. A 1 mg starting dose is community practice with compounded powder, used to gauge nausea. Inject into abdomen or thigh.
Timing
Best time to take
Inject at least 45 minutes before anticipated sexual activity. [7] How long each dose works is not known; the label lets each person choose the timing based on their own response and side effects such as nausea. [7]
With food?
Taking PT-141 on an empty stomach may increase nausea. A light meal or snack beforehand can help reduce stomach upset without significantly affecting absorption.
If stacking
PT-141 is typically used as a standalone treatment. Its unique mechanism of action through melanocortin receptors means it doesn't directly interact with most other peptides, but consult your healthcare provider before combining with other treatments.
Adjusting your dose
Increase if
- You tolerate the starting dose with minimal nausea
- Effects feel insufficient after multiple tries at current dose
- Your healthcare provider recommends adjustment based on your response
Decrease if
- Nausea is severe or interferes with the experience
- You experience significant blood pressure increases
- Flushing or headaches are uncomfortable
- Side effects outweigh the benefits
Signs of right dose
- Noticeable increase in sexual desire within 1-2 hours
- Manageable or no nausea
- Enhanced arousal response during intimacy
- No significant blood pressure changes
Administration
How do I use PT-141 (Bremelanotide)?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—this is how the FDA-approved Vyleesi autoinjector delivers the dose
Best sites
Storage
Before reconstitution
Keep your PT-141 powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder remains stable for 2+ years when frozen.
After reconstitution
Compounded powder mixed with bacteriostatic water: refrigerate at 36-46°F (2-8°C), never freeze, keep away from light, and use within 30 days. The FDA-approved VYLEESI autoinjector is different: store it at or below 77°F (25°C), do not freeze, and protect it from light. [7]
Signs of degradation — discard the vial
Sample daily schedule
45-60 minutes before anticipated intimacy
1.75 mg (standard FDA-approved dose) injection
Site: Abdomen or thigh
PT-141 is used on demand, not on a daily schedule, at least 45 minutes before sexual activity. [7] How long each dose works is not known. Do not take more than one dose in 24 hours or more than 8 doses a month. [7] Stop after 8 weeks if there is no improvement. [7]
Safety
Is PT-141 (Bremelanotide) safe?
Side effects
Commonly reported: Nausea, Facial flushing, Headache, Injection site reactions
Less common: Skin darkening (hyperpigmentation)
Stop and seek help if
- Severe nausea that makes the experience unpleasant or affects your health
- Significant blood pressure increases, especially if you feel chest discomfort or severe headache
- Noticeable skin darkening that concerns you (may be irreversible)
- Any signs of allergic reaction—hives, swelling, difficulty breathing
- The medication isn't providing the desired effect after multiple attempts
- You become pregnant or are trying to conceive
PT-141 (Vyleesi) is an FDA-approved medication, but it should be used under healthcare provider supervision. This information is educational—always consult your doctor about starting, stopping, or adjusting any medication. Report any unexpected side effects to your healthcare provider.
Flagged pairings
- Melanotan II — Both act on melanocortin receptors. Combining them increases risk of side effects including nausea, blood pressure changes, and hyperpigmentation. Avoid using together.
- Blood pressure medications — PT-141 affects blood pressure. Combining with antihypertensives may have unpredictable effects. Use only under medical supervision with monitoring.
- Oral naltrexone — Bremelanotide can significantly lower oral naltrexone levels. Avoid combining it with naltrexone products for alcohol or opioid addiction, because naltrexone treatment could fail [7]
- PDE5 inhibitors (Viagra, Cialis) — Both affect cardiovascular parameters. While sometimes combined in research for ED, this should only be done under medical supervision due to additive effects.
- MAO inhibitors — PT-141 affects dopamine and norepinephrine release. MAOIs can dangerously amplify these effects. Avoid combining.
Published research
What the studies show
Kingsberg SA, Clayton AH, Portman D · 2019
The landmark RECONNECT trials that led to FDA approval. Over 1,200 premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduction in distress compared to placebo. The 1.75mg dose delivered real benefits where it mattered most.
Simon JA, Kingsberg SA, Portman D · 2019
The 52-week extension study showed PT-141 maintained its effectiveness over time without developing tolerance. No new safety signals emerged with long-term use, and improvements in desire and reduced distress persisted throughout.
Dhillon S, Keam SJ · 2019
This comprehensive review covered PT-141's journey from lab to FDA approval. It explained how the drug works on MC4 receptors in the brain's desire circuits—a completely novel mechanism compared to existing sexual health treatments.
Pfaus JG, Sadiq A, Spana C · 2022
Deep dive into how PT-141 actually works in the brain. It activates MC4 receptors in the hypothalamus, triggering dopamine release in areas that control sexual motivation. This explains why it enhances desire itself, not just physical response.
Koochaki P, Revicki D, Wilson H · 2021
Real-world feedback from clinical trial participants. Women reported meaningful improvements in their sexual experiences and quality of life. Most felt the benefits outweighed the side effects, particularly nausea.
AMAG Pharmaceuticals (FDA) · 2019
Original 2019 VYLEESI label: 1.75 mg subcutaneously by autoinjector at least 45 minutes before sexual activity, at most once in 24 hours and 8 times a month, for premenopausal women with acquired, generalized HSDD.
Cosette Pharmaceuticals / U.S. Food and Drug Administration · 2025
For premenopausal women with acquired, generalized HSDD; not indicated for postmenopausal women, men, or to enhance sexual performance. 1.75 mg by autoinjector at least 45 minutes before sexual activity; at most one dose in 24 hours and 8 per month; stop after 8 weeks without improvement. Contraindicated in uncontrolled hypertension or known cardiovascular disease. BP rises up to 6/3 mmHg (peak 2-4 h) and heart rate falls up to 5 bpm, resolving within 12 h. Nausea 40% (21% after the first dose, about 3% after later doses), flushing 20%, injection-site reactions 13%, headache 11%, vomiting 5%. Focal hyperpigmentation 1% at up to 8 doses a month, 38% with 8 daily doses. Lowers exposure to oral naltrexone. Mechanism in HSDD unknown; most relevant receptors MC1R and MC4R. Store at or below 25 C.
Head to head
PT-141 (Bremelanotide) compared
Want the full picture?
The complete PT-141 (Bremelanotide) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.